AzTrials
AzTrials

Respiratory Muscle Blood FlowCRESTNCT01321411

Clinical Respiratory Evaluation Using Spectroscopy Trial

An observational study of Respiratory Muscle Blood Flow, run by University of British Columbia.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Respiratory muscles (the muscles used to breathe) need more blood (and oxygen) when their workload increases. It is difficult to measure respiratory muscle blood flow (RMBF) without invasive techniques. Read more about this study

Who is it for?
Ages 19 years and olderHealthy volunteers can take part
Conditions the study is for
Respiratory Muscle Blood Flow
What is being tested?
Near Infrared Spectroscopy
How many people
0 participants
Where
No sites listed yet
Study dates
Feb 2012to Sep 2012
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Critically Ill and Health Volunteers

Who may be able to join

  • Healthy Volunteers
  • 19 years of age or older
  • Informed Consent Obtained
  • No history of cardiopulmonary disease
  • No history of smoking
  • Critically Ill
Show all 9Show fewer
  • 19 years of age or older
  • Informed Consent Obtained
  • Total pulmonary system resistance (as measured through the mechanical ventilator circuit) of 2-8 cmH20/L/second OR Total pulmonary system static compliance (as measured through the mechanical ventilator circuit) of 20-60 ml/cmH20

Who cannot join

  • Esophageal lesions or esophageal surgery within the last 6 months
  • Morbid obesity - defined as a Body Mass Index (BMI) > 40
  • Allergy to any of the following: sulpha medications, penicillin, contrast dye, or iodine

About this study

Respiratory muscles (the muscles used to breathe) need more blood (and oxygen) when their workload increases. It is difficult to measure respiratory muscle blood flow (RMBF) without invasive techniques. We will evaluate a new, much less invasive technique to measure RMBF in 2 groups: Healthy Volunteers and Critically Ill patients on breathing machines. The purpose of this study is to determine the accuracy of this new monitoring technique called Near Infrared Spectroscopy Utilizing Indocyanine Green Dye when compared with traditional measurements. The information gained from this study will help us to provide better care to patients with severe lung problems.

Read the detailed description

PURPOSE To demonstrate the relationship between Respiratory Muscle Blood Flow and Work of Breathing using Near Infrared Spectroscopy utilizing Indocyanine Green Dye NIRS-ICG.

HYPOTHESIS AND OBJECTIVES

HYPOTHESIS #1: In subjects with normal respiratory muscle function (healthy volunteers) RMBF as measured by the NIRS-ICG technique will vary directly with work of breathing (WOB) as measured by changes in transpulmonary pressure gradients and as measured by Esophageal and Surface EMG.

Objective #1: To measure and demonstrate the relationship between RMBF and WOB/EMG in healthy volunteers simulating abnormal pulmonary resistance.

Objective #2: To measure and demonstrate the relationship between RMBF and WOB in healthy volunteers simulating abnormal pulmonary compliance.

HYPOTHESIS #2: In subjects with abnormal respiratory muscle function (weaning from mechanical ventilation after exacerbations of COPD or ARDS) RMBF as measured by the NIRS-ICG technique will vary with work of breathing as measured by changes in transpulmonary pressure gradients and as measured by Esophageal and Surface EMG.

Objective #3: To measure and demonstrate the relationship between RMBF and WOB in clinical subjects with abnormal pulmonary resistance (weaning from mechanical ventilation after COPD exacerbation).

Objective #4: To measure and demonstrate the relationship between RMBF and WOB in clinical subjects with abnormal pulmonary compliance (weaning from mechanical ventilation after ARDS).

HYPOTHESIS #3: We speculate, based on previous authors, that the blood flow rates in respiratory muscles for a given WOB will be different in clinical populations that in healthy volunteers. We hypothesize that the slope of the linear regression analysis relating BFI to WOB (both transpulmonary pressure gradients and EMG) will be "steeper" in clinical populations, suggesting that one reason for respiratory failure and weaning difficulties in these populations may be inefficient respiratory muscle oxygen utilization.

Objective #5: To demonstrate that the RMBF-WOB relationships in clinical populations will be different from that measured in healthy volunteers.

JUSTIFICATION To date, the measurement of regional blood flow and oxygen utilization has proven difficult. Nowhere is this more true than in the measurement of the regional blood flow and oxygen utilization of the respiratory muscles. Much of what we know about Respiratory Muscle Blood Flow (RMBF) stems from animal investigations or human research requiring highly invasive methods. The development of a minimally invasive technique for the measurement of RMBF has the potential to add significantly to our knowledge of respiratory energetics in research and clinical settings.

Near infrared spectroscopy (NIRS) can be used to measure the absorption of electromagnetic energy in the near infrared range (650 to 1000 nm) by in vivo chromophores. When assessing regional tissue oxygenation, NIRS assesses the amount of emitted energy absorbed in the range associated with hemoglobin (760 nm) and with deoxyhemoglobin (800 nm). The ratio of these amounts of absorbed light can be used to generate an index of tissue oxygenation/deoxygenation. Indocyanine green dye is a synthetic chromophore that absorbs energy in the infrared spectrum (805 nm). Guenette et al. measured the accumulation of ICG in respiratory muscles using NIRS while the concentration of ICG in the arterial blood was measured using photodensitometry. This technique has the advantage of being able to quantify absolute muscle blood flow with simultaneous measures of cardiac output, thereby allowing the calculation of absolute regional blood flows and absolute rates of regional oxygen uptake. The practicality of this technique in healthy volunteers is complicated by with the need for blood withdrawals and re-infusions as well as arterial cannulation and the measurement of cardiac output.

To avoid the logistical difficulties of arterial cannulation and central venous cannulation (required for the determination of cardiac output), a relative Blood Flow Index (BFI) has been proposed. The BFI method is a minimally invasive alternative and was first developed for rapid and repeated bedside estimation of cerebral blood flow. The BFI is derived from a transcutaneously measured NIRS ICG signal and does not require arterial cannulation or the measurement of cardiac output. BFI is a relative measure of blood flow as absolute flow cannot be determined unless arterial ICG concentration is measured.

Previous analyses have compared BFI and absolute muscle blood flow determined using NIRS and ICG and demonstrated strong agreement between BFI and NIRS derived absolute muscle blood flow. To date, no study has looked at the relationship between NIRS-ICG derived BFI values and respiratory workload as measured by esophageal and surface EMG (EEMG-SEMG) in subjects with abnormal compliance or resistance or in clinical populations.

Chronic Obstructive Pulmonary Disease (chronic bronchitis and emphysema), is a pathologic condition characterized by lung parenchyma destruction and abnormal airway narrowing that leads to a limitation of air. In clinical practice, COPD is defined by its characteristically low airflow and abnormal pulmonary system resistance during lung function tests. In contrast to asthma, this limitation is poorly reversible and progresses over time. COPD is the 4th leading cause of death amongst Canadians. Severe exacerbations of COPD may require mechanical ventilation and intensive care unit admission.

Acute Respiratory Distress Syndrome (ARDS) is a severe lung disease caused by both direct and indirect inflammatory injury. It is characterized by inflammation of the lung parenchyma leading to impaired gas exchange and abnormal respiratory system compliance. Hypoxemia and the release of systemically active cytokines frequently result in multiple organ failure and death. ARDS typically requires mechanical ventilation and admission to an intensive care unit.

Patients with COPD or ARDS that require mechanical ventilation are at high risk of death either from their disease or from complications during critical illness. Those that survive the acute phase of their illness often require prolonged mechanical ventilation and often have difficulty weaning from ventilator support. While lung parenchymal abnormalities and deconditioning are significant components of this "weaning failure", respiratory muscle strength, and potentially respiratory muscle blood flow, may play a role.

RESEARCH METHOD We will conduct a series of four studies to demonstrate the effectiveness of the Near Infrared Spectroscopy Indocyanine Green Dye (NIRS-ICG) technique for the non-invasive measurement of Respiratory Muscle Blood Flow (RMBF). The first two studies will occur in healthy volunteers and the second two studies will occur in clinical populations (mechanically ventilated patients recovering from exacerbations of COPD or recovering from ARDS). The first two studies will occur in our respiratory physiology laboratory (the Health and Integrative Physiology Laboratory at the University of British Columbia) and the second two will occur in the Intensive Care Unit (ICU) at VGH.

Being tested
Near Infrared Spectroscopy
Keywords
Respiratory Muscle Blood Flow, Work of Breathing, Near Infrared Spectroscopy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Near Infrared SpectroscopyOther

    Healthy Volunteers:

    Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.

    Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.

  • Near Infrared SpectroscopyOther

    Clinical Volunteers:

    Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.

    Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.

Study groups in NCT01321411
Study groupRoleWhat they receive
1. ARDS/COPDCritically ill patients with either ARDS or COPD weaning from mechanical ventilation.
Receives: Other: Near Infrared Spectroscopy
2. Healthy VolunteersNot described
Receives: Other: Near Infrared Spectroscopy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measure and demonstrate the relationship between RMBF and WOB

    To measure and demonstrate the relationship between RMBF and WOB in healthy volunteers simulating abnormal pulmonary resistance and compliance AND in critically ill subjects with abnormal respiratory muscle function (weaning from mechanical ventilation after exacerbations of COPD or ARDS).

    Measured: 3 hours

Secondary outcomes (1)
  1. Demonstrate differences in RMBF-WOB between 2 cohorts

    We speculate that the blood flow rates in respiratory muscles for a given WOB will be different in clinical populations that in healthy volunteers.

    Objective: To demonstrate that the RMBF-WOB relationships in clinical populations will be different from that measured in healthy volunteers.

    Measured: 3 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Mar 2011 (estimated)
  2. Study startFeb 2012
  3. Primary completionJul 2012 (estimated)
  4. Study completionSep 2012 (estimated)

Why it stopped: Not started and now discontinued

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01321411
Sponsor's protocol ID
H10-03356
Acronym
CREST
Status last verified
Mar 2014
First submitted
21 Mar 2011
Last updated
6 Mar 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Respiratory Muscle Blood Flow, run by University of British Columbia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 6 Mar 2014. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measure and demonstrate the relationship between RMBF and WOB (time frame: 3 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2014.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in